CL2011002792A1 - Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros. - Google Patents

Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros.

Info

Publication number
CL2011002792A1
CL2011002792A1 CL2011002792A CL2011002792A CL2011002792A1 CL 2011002792 A1 CL2011002792 A1 CL 2011002792A1 CL 2011002792 A CL2011002792 A CL 2011002792A CL 2011002792 A CL2011002792 A CL 2011002792A CL 2011002792 A1 CL2011002792 A1 CL 2011002792A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
compounds
obesity
pde10
narcolepsy
Prior art date
Application number
CL2011002792A
Other languages
English (en)
Spanish (es)
Inventor
Gideon Shapiro
Amy Ripka
Richard Chesworth
Original Assignee
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Publication of CL2011002792A1 publication Critical patent/CL2011002792A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2011002792A 2009-05-07 2011-11-07 Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros. CL2011002792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17641309P 2009-05-07 2009-05-07

Publications (1)

Publication Number Publication Date
CL2011002792A1 true CL2011002792A1 (es) 2012-06-01

Family

ID=41549054

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002792A CL2011002792A1 (es) 2009-05-07 2011-11-07 Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros.

Country Status (32)

Country Link
US (3) US8343973B2 (en, 2012)
EP (3) EP2427454B1 (en, 2012)
JP (2) JP5628902B2 (en, 2012)
KR (1) KR101662699B1 (en, 2012)
CN (2) CN105125547A (en, 2012)
AU (1) AU2009345802B2 (en, 2012)
BR (1) BRPI0924617A8 (en, 2012)
CA (1) CA2761032A1 (en, 2012)
CL (1) CL2011002792A1 (en, 2012)
CO (1) CO6460744A2 (en, 2012)
CR (1) CR20110648A (en, 2012)
DK (2) DK2427454T3 (en, 2012)
EC (1) ECSP11011479A (en, 2012)
ES (2) ES2409404T3 (en, 2012)
HR (2) HRP20130482T1 (en, 2012)
HU (1) HUE026238T2 (en, 2012)
IL (2) IL216149A (en, 2012)
ME (1) ME02375B (en, 2012)
MX (1) MX2011011755A (en, 2012)
MY (1) MY183910A (en, 2012)
NZ (1) NZ596753A (en, 2012)
PE (1) PE20120900A1 (en, 2012)
PH (1) PH12013501321B1 (en, 2012)
PL (2) PL2427454T3 (en, 2012)
PT (2) PT2617420E (en, 2012)
RS (2) RS54529B1 (en, 2012)
RU (1) RU2531274C2 (en, 2012)
SG (1) SG175900A1 (en, 2012)
SI (2) SI2617420T1 (en, 2012)
SM (2) SMT201300070B (en, 2012)
WO (1) WO2010128995A1 (en, 2012)
ZA (1) ZA201108920B (en, 2012)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297133B1 (en) * 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
DK2427454T3 (da) 2009-05-07 2013-06-17 Envivo Pharmaceuticals Inc Heterocykliske phenoxymethylforbindelser
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661564A1 (fr) * 1999-11-05 2006-05-31 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Nouveaux composés hétérocycliques et leur application à titre de médicaments
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1541149A1 (en) 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
JP4302762B2 (ja) 2005-01-07 2009-07-29 ファイザー・プロダクツ・インク 複素環式芳香族キノリン化合物およびpde10阻害剤としてのその使用
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
EP2297133B1 (en) * 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
DK2427454T3 (da) 2009-05-07 2013-06-17 Envivo Pharmaceuticals Inc Heterocykliske phenoxymethylforbindelser
RU2012109233A (ru) * 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
ES2879314T3 (es) * 2010-08-18 2021-11-22 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina

Also Published As

Publication number Publication date
IL216149A0 (en) 2012-01-31
CN105125547A (zh) 2015-12-09
DK2617420T3 (da) 2015-12-07
US20130143888A1 (en) 2013-06-06
JP2012526107A (ja) 2012-10-25
EP2427454A1 (en) 2012-03-14
RS54529B1 (en) 2016-06-30
PH12013501321A1 (en) 2014-08-27
RU2531274C2 (ru) 2014-10-20
PE20120900A1 (es) 2012-08-14
KR20120027268A (ko) 2012-03-21
PL2617420T3 (pl) 2016-04-29
HK1186981A1 (en) 2014-03-28
MY183910A (en) 2021-03-17
BRPI0924617A8 (pt) 2017-10-03
HUE026238T2 (en) 2016-06-28
CO6460744A2 (es) 2012-06-15
CA2761032A1 (en) 2010-11-11
WO2010128995A1 (en) 2010-11-11
PT2427454E (pt) 2013-06-20
JP5628902B2 (ja) 2014-11-19
EP2617420A1 (en) 2013-07-24
NZ596753A (en) 2013-09-27
US20100292238A1 (en) 2010-11-18
RU2011149637A (ru) 2013-06-20
ME02375B (me) 2016-06-20
JP2015038112A (ja) 2015-02-26
AU2009345802B2 (en) 2016-05-26
IL244059A0 (en) 2016-04-21
CN102459242B (zh) 2015-08-26
SG175900A1 (en) 2011-12-29
US8946222B2 (en) 2015-02-03
RS52838B (en) 2013-10-31
PT2617420E (pt) 2015-12-18
CN102459242A (zh) 2012-05-16
US20150322069A1 (en) 2015-11-12
PL2427454T3 (pl) 2013-09-30
SMT201300070B (it) 2013-09-06
SMT201600031B (it) 2016-02-25
ECSP11011479A (es) 2011-12-30
DK2427454T3 (da) 2013-06-17
AU2009345802A1 (en) 2011-12-15
SI2427454T1 (sl) 2013-08-30
EP3020716A1 (en) 2016-05-18
MX2011011755A (es) 2012-03-16
IL216149A (en) 2016-02-29
US8343973B2 (en) 2013-01-01
PH12013501321B1 (en) 2014-08-27
BRPI0924617A2 (en, 2012) 2017-07-11
HK1167402A1 (en) 2012-11-30
EP2617420B1 (en) 2015-09-23
KR101662699B1 (ko) 2016-10-05
ES2554788T3 (es) 2015-12-23
ES2409404T3 (es) 2013-06-26
HRP20151273T1 (hr) 2016-01-29
ZA201108920B (en) 2012-08-29
SI2617420T1 (sl) 2016-02-29
JP5943053B2 (ja) 2016-06-29
EP2427454B1 (en) 2013-03-20
CR20110648A (es) 2012-03-28
HRP20130482T1 (en) 2013-08-31

Similar Documents

Publication Publication Date Title
CL2011002792A1 (es) Compuestos derivados de metoxifenil furan-3-(2h)-ona, inhibidores de fosfodiesterasa 10 (pde10); composicion farmaceutica que comprende a uno de los compuestos; y uso de la composicion farmaceutica en la preparacion de medicamentos para tratar trastornos de la alimentacion, obesidad, juego compulsivo, narcolepsia, entre otros.
JO3073B1 (ar) مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
PH12015500813A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
GB201209587D0 (en) Therapeutic compounds
MX2011010150A (es) Aplicaciones terapeuticas de derivados de quinazolinodiona.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MX2008012332A (es) Tiazolil-dihidro-indazoles.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
EA201491026A1 (ru) Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1